Earnings ·
Xencor reports Q3 net income of $39.4M on $116.5M revenue driven by royalties and milestones
XNCRXencor Inc
Xencor reported third-quarter 2026 net income attributable to the company of $39.4 million, or $0.50 per diluted share, compared to a net loss of $6.0 million in the prior-year period. Revenue surged to $116.5 million from $21.0 million, primarily due to royalty revenue from Alexion and Incyte and milestone payments from Astellas. Cash, cash equivalents, and marketable debt securities totaled $555.7 million at quarter-end. The company expects to end 2026 with between $480 million and $500 million in liquidity, sufficient to fund operations into 2029. Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases.